This was the stock's third consecutive day of losses.

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen (AMGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an analysis of AMGN stock now.

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.

A campaign backed by Kyowa Kirin, Amgen and Sanofi is calling on prominent organizations with medical websites to bring their ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...